213Bi-CETN1

N/A

Report date: 2025/11/10 17:58:38

Base Information

Drug Name213Bi-CETN1

Drug Alias NameN/A

ClassificationRadiation-emitting products > Nuclides > Bismuth > 213BiRadiation-emitting products > Radioactive therapeutic agentRadiation-emitting products > Radionuclide Drug Conjugates +[4]

Mechanisms of ActionAnti-Centrin-1

TargetsCentrin-1

Therapy Area/IndicationsPancreatic Neoplasms

Global Approved IndicationsN/A

Approved Indications in ChinaN/A

Original Approved Country/TerritoryN/A

Original Approved DateN/A

Country/TerritoryCanadaUnited States

CombinationsNo

Global Highest StatusPreclinical

Highest Status in ChinaN/A

Originator CompaniesRadimmune Therapeutics Inc University Of Saskatchewan

China Registration ClassN/A

Develop Information

Active CompaniesRadimmune Therapeutics Inc University Of Saskatchewan

Inactive CompaniesN/A

Active IndicationsPancreatic Neoplasms

Inactive IndicationsN/A

Other Information

ATC CodeN/A